An Open-label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory Cd22-positive Acute Lymphoblastic Leukemia (All)

The main purpose of this research study is to learn if Inotuzumab Ozogamicin is a more effective treatment when compared to chemotherapies commonly used in patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL). Also, what the side effects are associated to inotuzumab ozogamicin treatment and how it distributes through the body will be assessed.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : inotuzumab ozogamicin
  • drug : cytarabine and mitoxantrone
  • drug : HIDAC (high dose cytarabine)
  • drug : FLAG (fludarabine, cytarabine and G-CSF)

Phase: Phase 3

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- CD22 expression - Adequate liver and renal functions

External Links

Explore related trials

Contact information

Primary Contact:

Ying Hao 650-723-0646

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: